Immunic, Inc.
IMUX Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$7.41
KIRA · Stoqly’s AI analyst, in plain words
- Immunic, Inc. lost $97.2M in fiscal 2025.
- Free cash flow was −$86.0M in fiscal 2025, — of revenue.
Market cap
$315M
P/E
3.6x
Revenue
—
Net income
−$97.2M
Free cash flow
−$86.0M
Operating margin
—
Immunic, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$97.2M
No. It lost money last year.
How is the share priced?
3.6x
One share costs 3.6 times its yearly profit per share.
What Immunic, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 26, 2026
- Legal name
- IMMUNIC, INC.
- CIK
- 0001280776
Immunic, Inc. · IMUX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$92.9M | −$120M | −$93.6M | −$101M | −$97.2M |
| Diluted EPS | −$3.93 | −$3.78 | −$2.11 | −$1.00 | −$0.62 |
| Cash | |||||
| Cash from operations | −$83.2M | −$65.1M | −$70.8M | −$84.8M | −$85.8M |
| Capital expenditure | $0.1M | $0.1M | $0.3M | $0.3M | $0.2M |
| Free cash flow | −$83.3M | −$65.3M | −$71.2M | −$85.0M | −$86.0M |
| Share count change | 51.0% | 34.5% | 39.3% | 126.0% | 55.4% |
| Debt and strength | |||||
| Cash and short-term investments | $86.9M | $107M | $46.7M | $35.7M | $15.5M |
| Shareholders' equity | $127M | $114M | $28.9M | $18.4M | −$6.7M |
| Current ratio | 9.2x | 9.6x | 2.1x | 1.8x | 0.7x |
| Returns and quality | |||||
| Return on equity | −65.0% | −100.0% | −131.3% | −424.4% | −1,653.1% |
| Return on tangible equity | −98.7% | −105.9% | −323.6% | −545.4% | — |
| Altman Z'' | 6.5 | −0.1 | −32.4 | −53.3 | −113.7 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Immunic, Inc. · IMUX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $7.41 a share, the company is worth $315M: 3.6 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001280776). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.